E-LIB Suche - Ergebnisse für: Saba, N.F.

1

HyperlynX: A Phase 1b Safety Study of Xevinapant, Weekly Ci..:

Saba, N.F. ; Sukari, A. ; Forget, F....
International Journal of Radiation Oncology*Biology*Physics. 118 (2024) 5 - p. e21 , 2024

Link: https://doi.org/10.1016/..

2

Pembrolizumab and Cabozantinib in Recurrent Metastatic Head..:

Saba, N.F. ; Ekpenyong, A. ; McCook, A....
International Journal of Radiation Oncology*Biology*Physics. 118 (2024) 5 - p. e3 , 2024

Link: https://doi.org/10.1016/..

3

Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone..:

Saba, N.F. ; Harrington, K. ; Licitra, L....
International Journal of Radiation Oncology*Biology*Physics. 118 (2024) 5 - p. e40-e41 , 2024

Link: https://doi.org/10.1016/..

4

Biomarker-Driven Radiation Therapy Dose Reduction after Tra..:

Bates, J.E. ; Stokes, W.A. ; McDonald, M.W....
International Journal of Radiation Oncology*Biology*Physics. 118 (2024) 5 - p. e15 , 2024

Link: https://doi.org/10.1016/..

5

A Phase 1 Dose-escalation and Expansion Study of CUE-101, G..:

Colevas, A.D. ; Chung, C.H. ; Adkins, D....
International Journal of Radiation Oncology*Biology*Physics. 118 (2024) 5 - p. e87 , 2024

Link: https://doi.org/10.1016/..

6

A Phase 2 Multi-Center, Placebo-Controlled, Randomized Stud..:

Saba, N.F. ; Gupta, N. ; Ravishankar, B....
International Journal of Radiation Oncology*Biology*Physics. 118 (2024) 5 - p. e7-e8 , 2024

Link: https://doi.org/10.1016/..

7

Phase 1/2 Study of Pepinemab in Combination with Pembrolizu..:

Fisher, T.L. ; Evans, E.E. ; Mallow, C....
International Journal of Radiation Oncology*Biology*Physics. 112 (2022) 5 - p. e36 , 2022

Link: https://doi.org/10.1016/..

8

Institutional Comparison between Radiation with Concurrent ..:

Abousaud, M. ; Shepherd, M. ; Lozano, F....
International Journal of Radiation Oncology*Biology*Physics. 112 (2022) 5 - p. e12-e13 , 2022

Link: https://doi.org/10.1016/..

9

155P BNT113 + pembrolizumab as first-line treatment in pati..:

Klinghammer, K. ; Saba, N.F. ; Castelluci, E....
Immuno-Oncology and Technology. 16 (2022) - p. 100267 , 2022

Link: https://doi.org/10.1016/..

10

Does Operability Status Influence Outcomes in Patients with..:

Schlafstein, A. ; Goyal, S. ; Amini, A....
International Journal of Radiation Oncology*Biology*Physics. 112 (2022) 5 - p. e16 , 2022

Link: https://doi.org/10.1016/..

11

Factors Predictive of Primary Therapeutic Modality in Early..:

Bates, J.E. ; Stokes, W.A. ; Remick, J.S....
International Journal of Radiation Oncology*Biology*Physics. 112 (2022) 5 - p. e22-e23 , 2022

Link: https://doi.org/10.1016/..

12

Reduced Aspiration Rates for 50 Gy Postoperative Radiation ..:

Hutcheson, K.A. ; Peterson, C.B. ; Barbon, C.E....
International Journal of Radiation Oncology*Biology*Physics. 114 (2022) 3 - p. S27-S28 , 2022

Link: https://doi.org/10.1016/..

13

Patient-reported Outcomes in Oropharyngeal Cancer Treated W..:

McDonald, M.W. ; Bates, J.E. ; Patel, M.R....
International Journal of Radiation Oncology*Biology*Physics. 113 (2022) 1 - p. e2 , 2022

Link: https://doi.org/10.1016/..

14

Outcomes Stratification of Head and Neck Cancer Using Pre- ..:

Qian, D.C. ; Ulrich, B.C. ; Peng, G....
International Journal of Radiation Oncology*Biology*Physics. 111 (2021) 3 - p. S143-S144 , 2021

Link: https://doi.org/10.1016/..

15

Does Operability Status Influence Outcomes in Patients With..:

Schlafstein, A. ; Goyal, S. ; Amini, A....
International Journal of Radiation Oncology*Biology*Physics. 111 (2021) 3 - p. e366 , 2021

Link: https://doi.org/10.1016/..